Sales of darolutamide started in the EU and Japan – Orion receives total of EUR 28 million milestones

On May 20, 2020 Orion Corporation and Bayer reported Sales of Nubeqa (darolutamide), jointly developed for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC), has started in the EU and Japan (Press release, Orion , MAY 20, 2020, View Source [SID1234558328]). From the first commercial sales in the EU Orion receives from Bayer a EUR 20 million and from the first commercial sales in Japan a EUR 8 million milestone. Orion will book the milestones in its second quarter 2020 result. The booking has no impact on Orion’s outlook for 2020 as the total of EUR 28 million milestones have been included in the financial guidance provided by the company.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!